You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 24, 2024

~ Buy the VYLEESI (AUTOINJECTOR) (bremelanotide acetate) Drug Profile, 2024 PDF Report in the Report Store ~

VYLEESI (AUTOINJECTOR) Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Vyleesi (autoinjector) patents expire, and what generic alternatives are available?

Vyleesi (autoinjector) is a drug marketed by Cosette and is included in one NDA. There are five patents protecting this drug.

This drug has eighty-one patent family members in twenty-six countries.

The generic ingredient in VYLEESI (AUTOINJECTOR) is bremelanotide acetate. One supplier is listed for this compound. Additional details are available on the bremelanotide acetate profile page.

DrugPatentWatch® Generic Entry Outlook for Vyleesi (autoinjector)

Vyleesi (autoinjector) was eligible for patent challenges on June 21, 2023.

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for VYLEESI (AUTOINJECTOR)?
  • What are the global sales for VYLEESI (AUTOINJECTOR)?
  • What is Average Wholesale Price for VYLEESI (AUTOINJECTOR)?
Summary for VYLEESI (AUTOINJECTOR)
International Patents:81
US Patents:5
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
DailyMed Link:VYLEESI (AUTOINJECTOR) at DailyMed
Drug patent expirations by year for VYLEESI (AUTOINJECTOR)
Pharmacology for VYLEESI (AUTOINJECTOR)

US Patents and Regulatory Information for VYLEESI (AUTOINJECTOR)

VYLEESI (AUTOINJECTOR) is protected by five US patents and one FDA Regulatory Exclusivity.

Patents protecting VYLEESI (AUTOINJECTOR)

Uses of bremelanotide in therapy for female sexual dysfunction
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD)


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATING ACQUIRED, GENERALIZED HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) IN A PREMENOPAUSAL FEMALE PATIENT WITH CONTROLLED HYPERTENSION BY INJECTING BREMELANOTIDE MORE THAN ONCE WITH AT LEAST 24 HOURS BETWEEN DOSES AND NO MORE THAN 8 DOSES PER MONTH

Compositions and methods for treatment of sexual dysfunction
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Uses of bremelanotide in therapy for female sexual dysfunction
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD)

Uses of bremelanotide in therapy for female sexual dysfunction
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD)

FDA Regulatory Exclusivity protecting VYLEESI (AUTOINJECTOR)

NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cosette VYLEESI (AUTOINJECTOR) bremelanotide acetate SOLUTION;SUBCUTANEOUS 210557-001 Jun 21, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Cosette VYLEESI (AUTOINJECTOR) bremelanotide acetate SOLUTION;SUBCUTANEOUS 210557-001 Jun 21, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Cosette VYLEESI (AUTOINJECTOR) bremelanotide acetate SOLUTION;SUBCUTANEOUS 210557-001 Jun 21, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Cosette VYLEESI (AUTOINJECTOR) bremelanotide acetate SOLUTION;SUBCUTANEOUS 210557-001 Jun 21, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Cosette VYLEESI (AUTOINJECTOR) bremelanotide acetate SOLUTION;SUBCUTANEOUS 210557-001 Jun 21, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for VYLEESI (AUTOINJECTOR)

See the table below for patents covering VYLEESI (AUTOINJECTOR) around the world.

Country Patent Number Title Estimated Expiration
World Intellectual Property Organization (WIPO) 2005117935 ⤷  Sign Up
Poland 2916856 ⤷  Sign Up
China 101010095 ⤷  Sign Up
European Patent Office 2916856 UTILISATIONS DE BRÉMÉLANOTIDE DANS UNE THÉRAPIE DE DYSFONCTIONNEMENT SEXUEL FÉMININ (USES OF BREMELANOTIDE IN THERAPY FOR FEMALE SEXUAL DYSFUNCTION) ⤷  Sign Up
Israel 180490 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.